TFA Therapeutics, Inc. (RAJAF): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

Older than the company's other figures. The latest EBITDA is for the year ended 2023-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report Depreciation & Amortization, which EBITDA is computed from, under the concepts TickerFacts maps.

$284.6K
Year ended 2023-12-31
2022-12-31: -$390.6K2023-12-31: $284.6K$284.6K
2022-12-31 EBITDA (USD) 2023-12-31
Period endedEBITDAChange YoYSource filing
2023-12-31$284.6Kn/m2026-05-15, From 2023-01-01
2022-12-31-$390.6Kn/a2025-09-23, From 2022-01-01